Automation, Access, and the Future of Manufacturing
Manufacturing can make or break the future of cell and gene therapy. In this episode, Stuart sits down with two expert guests to share how smart design, automation, and closed systems are helping to lower costs, reduce complexity, and make therapies more accessible. From scaling strategies to operator-friendly technology, they reveal why manufacturing isn’t just a back-end process, but a critical part of therapy development from day one.Guests:Professor Mark Lowdell, CSO InMune Bio IncLuc Henry, Founder and CEO at Limula
-------- Â
37:25
--------
37:25
Scaling Cell & Gene Therapies: From Breakthroughs to the Mass Market
In this two-part series, host Stuart Lowe examines the barriers and breakthroughs that will determine whether cell and gene therapies can scale. From smarter manufacturing to new policy frameworks, join leading experts as they discuss what must change for CGTs to deliver on their full potential.
-------- Â
3:32
--------
3:32
From Promise to Practice – AI's Impact on Cell and Gene Therapy Development
In this episode, Stuart explores the adoption of generative AI in the pharmaceutical industry, with a special focus on cell and gene therapy. While the application of AI for drug discovery has been well documented and a source of considerable investment for the pharmaceutical sector, we are only just starting to see its impact for therapy developers. A 2024 report from McKinsey Global Institute estimates that generative AI could generate up to $100 billion in economic value for pharma and medical product companies, and therapy developers are eager to see these benefits sooner rather than later, no more so than in the complex and challenging field of cell and gene therapies. With the help of two expert guests, Stuart will uncover how AI is being used in the industry today, and where it could go in the future. Guests:Ken Harris, Chief Strategy Officer and Head of AI at OmniaBioSean Bedingfield, PhD, Senior Advisor at Eli Lilly Genetic Medicine
-------- Â
34:36
--------
34:36
From Plastics to Partnerships - The Path to Sustainability in Biopharma
In this episode, host Stuart explores what the sustainability goals of Big Pharma mean for those organisations, and the companies that support them. With insights from Ryan Walker, Sustainability Program Leader at Cytiva, and Wenshu Xu, Drug Discovery Tools Team Lead at TTP, we review the progress made by the industry so far and some examples where innovative thinking has had an impact on operations. Topics include the challenge of tackling Scope 3 emissions, reducing the impact of single-use plastics, and how collaboration across the ecosystem is key to meeting ambitious sustainability targets.Guests:Ryan Walker, Sustainability Program Leader, CytivaWenshu Xu, Drug Discovery Tools Team Lead, TTP
-------- Â
40:05
--------
40:05
How Climate Change and AI are Driving Innovation in Biopharma
In this two-part series, host Stuart Lowe examines two factors testing the resilience of the biopharma industry. As society simultaneously navigates a green transition alongside an AI revolution, so the biopharma industry faces mounting pressure to address its carbon emissions, deploy cutting-edge digital technology, while streamlining operations. Along with his guests, discover the innovative approaches that are being taken to transform drug development and manufacturing.
What are the biggest challenges and opportunities facing the life sciences sector? How can we overcome these challenges while unlocking the opportunities? Join host Stuart Lowe and a roster of expert guests as they unpack the past, present and future of cell and gene therapy.
Ireland